Nouvelle déclaration d'incident
No de la demande: 2010-3452
Numéro de référence du titulaire d'homologation: PROSAR Case # 1-23538100
Nom du titulaire (nom légal complet, aucune abbréviation): Scotts Canada Ltd.
Adresse: 2000 Argentia Road, Plaza 5, Suite 101
Ville: Mississauga
État: Ontario
Pays: Canada
Code postal /Zip: L5N2R7
Incident chez l'humain
Pays: CANADA
État: ONTARIO
ARLA No d'homologation 27521 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Ortho Home Defense Max Perimeter Indoor Insect Control Ready-to-Use
Oui
Inconnu
Site: Res. - In Home / Rés. - à l'int. maison
Inconnu
Personne affectée
Sexe: Homme
Âge: >19 <=64 yrs / >19 <=64 ans
Système
>24 hrs <=3 days / >24 h <=3 jours
Inconnu
Oui
9
Day(s) / Jour(s)
Non professionnel
Contact avec la zone traitée
Quelle était l'activité? contact with furniture to which product had been applied
Inconnu
Peau
Unknown / Inconnu
Unknown / Inconnu
1-23538100- The reporter calls to indicate exposure to an insecticide containing the active ingredient permethrin. The reporter indicates he applied the product to his residential home and inside his vehicle fifteen days prior to the initial contact with the registrant. The reporter indicates he may have sat on furniture with still wet product applied. The caller does not, however, describe a discreet exposure incident. The caller reports two days after the initial application he developed symptoms of nausea, vertigo, and ¿lack of motor control" further described as he "could barely walk". He reports by the following day he was brought to the emergency room by ambulance and reports the doctors contacted regional poison control. The physicians were told by poison control the symptoms seen were inconsistent with exposure to this active ingredient. The reporter indicates he was hospitalized for the next nine days during which time he had blood tests (unspecified), a CT scan and many other unspecified tests all of which were reported to be within normal limits. The caller reports he was given no actual treatment during his stay in the hospital. The caller was advised the symptoms seen would not be expected following routine product use. He was advised of the low order of toxicity and concentration of the product. He was advised of topical symptoms that may be seen following immediately dermal contact and appropriate treatment/decontamination. He was advised to follow with his doctor for further treatment/diagnosis. The reporter did not respond to two separate follow up attempts. No further information is available.
Majeure